Published in Ment Retard Dev Disabil Res Rev on January 01, 2007
Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci (2012) 1.17
Down syndrome: the brain in trisomic mode. Nat Rev Neurosci (2012) 1.10
Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis (2011) 1.09
Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis (2011) 1.05
Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr (2010) 0.99
Neurological phenotypes for Down syndrome across the life span. Prog Brain Res (2012) 0.98
PCR prescreen for genotyping the Ts65Dn mouse model of Down syndrome. Biotechniques (2010) 0.98
A Sonic hedgehog (Shh) response deficit in trisomic cells may be a common denominator for multiple features of Down syndrome. Prog Brain Res (2012) 0.87
Antioxidants in Down syndrome. Biochim Biophys Acta (2011) 0.85
Increased male reproductive success in Ts65Dn "Down syndrome" mice. Mamm Genome (2010) 0.80
Down syndrome and the complexity of genome dosage imbalance. Nat Rev Genet (2016) 0.77
Involvement of Potassium and Cation Channels in Hippocampal Abnormalities of Embryonic Ts65Dn and Tc1 Trisomic Mice. EBioMedicine (2015) 0.77
Real-time imaging of Rab5 activity using a prequenched biosensor. ACS Chem Biol (2011) 0.75
Characterization of PTZ-induced seizure susceptibility in a down syndrome mouse model that overexpresses CSTB. PLoS One (2011) 0.75
DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome. Proc Natl Acad Sci U S A (2017) 0.75
Deleterious Effects of Chronic Folate Deficiency in the Ts65Dn Mouse Model of Down Syndrome. Front Cell Neurosci (2017) 0.75
Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron (2006) 3.51
NGF signaling in sensory neurons: evidence that early endosomes carry NGF retrograde signals. Neuron (2003) 3.23
The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. Genet Med (2009) 2.83
One at a time, live tracking of NGF axonal transport using quantum dots. Proc Natl Acad Sci U S A (2007) 2.74
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci (2004) 2.73
Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron (2010) 2.20
Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment. Crit Rev Toxicol (2008) 1.93
Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol (2004) 1.92
Long-distance retrograde neurotrophic signaling. Curr Opin Neurobiol (2005) 1.84
Synthesis and anticonvulsant activity of new 2-substituted-5- [2-(2-fluorophenoxy)phenyl]-1,3,4-oxadiazoles and 1,2,4-triazoles. Bioorg Med Chem Lett (2004) 1.82
Signaling endosome hypothesis: A cellular mechanism for long distance communication. J Neurobiol (2004) 1.63
Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction by modulating glutamate receptor recycling in Down's syndrome. Nat Med (2013) 1.61
Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J Comp Neurol (2009) 1.57
Errors in preparation and administration of intravenous medications in the intensive care unit of a teaching hospital: an observational study. Aust Crit Care (2008) 1.52
TrkB binds and tyrosine-phosphorylates Tiam1, leading to activation of Rac1 and induction of changes in cellular morphology. Proc Natl Acad Sci U S A (2006) 1.48
The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J Neurosci (2009) 1.46
An AUPN/ANA survey of department leader opinions on the health of US academic neurology. Neurology (2004) 1.40
Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J Comp Neurol (2007) 1.38
Synthesis and anticonvulsant activity of new 2-substituted-5-(2-benzyloxyphenyl)-1,3,4-oxadiazoles. Bioorg Med Chem Lett (2005) 1.36
The coming of age of axonal neurotrophin signaling endosomes. J Proteomics (2008) 1.35
Late onset neurodegeneration in the Cln3-/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res (2004) 1.32
Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J Comp Neurol (2009) 1.31
Mouse model of Timothy syndrome recapitulates triad of autistic traits. Proc Natl Acad Sci U S A (2011) 1.26
Comparative study of brain morphology in Mecp2 mutant mouse models of Rett syndrome. J Comp Neurol (2008) 1.26
Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. Cell Stem Cell (2009) 1.25
Neuronal plasticity and dendritic spines: effect of environmental enrichment on intact and postischemic rat brain. J Cereb Blood Flow Metab (2002) 1.24
Endophilin B1 as a novel regulator of nerve growth factor/ TrkA trafficking and neurite outgrowth. J Neurosci (2008) 1.20
Membrane targeting by APPL1 and APPL2: dynamic scaffolds that oligomerize and bind phosphoinositides. Traffic (2007) 1.20
Evidence for both neuronal cell autonomous and nonautonomous effects of methyl-CpG-binding protein 2 in the cerebral cortex of female mice with Mecp2 mutation. Neurobiol Dis (2009) 1.18
Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci (2012) 1.17
Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav (2012) 1.15
A functional dynein-microtubule network is required for NGF signaling through the Rap1/MAPK pathway. Traffic (2007) 1.15
Traffic at the intersection of neurotrophic factor signaling and neurodegeneration. Trends Neurosci (2003) 1.12
Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazoles as benzodiazepine receptor agonists. Bioorg Med Chem Lett (2005) 1.10
Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis (2011) 1.09
Design and synthesis of new 2-substituted-5-[2-(2-halobenzyloxy)phenyl]-1,3,4-oxadiazoles as anticonvulsant agents. Chem Pharm Bull (Tokyo) (2008) 1.09
Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Res (2010) 1.05
Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis (2011) 1.05
Illicium sesquiterpenes: divergent synthetic strategy and neurotrophic activity studies. Chemistry (2013) 1.04
Evaluation of Anti-nociceptive and Anti-inflammatory Activities of Novel Chalcone Derivatives. Iran J Pharm Res (2013) 1.00
The challenge of connecting the dots in the B.R.A.I.N. Neuron (2013) 0.99
Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. J Neurochem (2011) 0.99
Retrolinkin, a membrane protein, plays an important role in retrograde axonal transport. Proc Natl Acad Sci U S A (2007) 0.99
Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species. Biochemistry (2014) 0.98
Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12. Mamm Genome (2005) 0.96
Mouse models for Down syndrome-associated developmental cognitive disabilities. Dev Neurosci (2011) 0.95
Going the distance, or not, with neurotrophin signals. Cell (2004) 0.95
Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome. J Comp Neurol (2011) 0.94
Trafficking the NGF signal: implications for normal and degenerating neurons. Prog Brain Res (2004) 0.92
Enantioselective synthesis of (-)-jiadifenin, a potent neurotrophic modulator. Org Lett (2011) 0.92
Deficiencies in the region syntenic to human 21q22.3 cause cognitive deficits in mice. Mamm Genome (2010) 0.91
Sleep and EEG features in genetic models of Down syndrome. Neurobiol Dis (2007) 0.90
Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. J Clin Invest (2016) 0.87
Determination of impurities in illicit methamphetamine samples seized in Iran. Forensic Sci Int (2011) 0.85
Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits. Hum Mol Genet (2013) 0.83
Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome. Curr Opin Neurobiol (2012) 0.83
Potential use of γ-secretase modulators in the treatment of Alzheimer disease. Arch Neurol (2012) 0.83
Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests. Psychopharmacology (Berl) (2015) 0.81
Comparison [(3)H]-flumazenil binding parameters in rat cortical membrane using different separation methods, filtration and centrifugation. Nucl Med Biol (2013) 0.81
Zolpidem-induced suicide attempt: a case report. Daru (2013) 0.80
Genetic analysis of Down syndrome facilitated by mouse chromosome engineering. Bioeng Bugs (2012) 0.80
Aging and intellectual disability: insights from mouse models of Down syndrome. Dev Disabil Res Rev (2013) 0.79
Synthesis of a quaternary bis derivative of imipramine as a novel compound with potential anti-enuretic effect. J Pharm Pharmacol (2009) 0.75
Transgenic animals in pharmaceutical and biological research in iran. Iran J Pharm Res (2013) 0.75